New treatments for inflammation in age-related macular degeneration
Official title: Evaluation of New Anti-inflammatory Treatments for Age-Related Macular Degeneration
Funded at Ohio State University · NIH-10933407 · Data updated 2026-11-12
This study is working on a new injectable treatment for age-related macular degeneration (AMD) that uses tiny particles to help reduce inflammation and improve vision, making it easier for patients by cutting down on the number of injections they need.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | September 30, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $236,250 |
| NIH project number | 5R21EY035038-02 |
| Project ID | NIH-10933407 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with early-stage or atrophic age-related macular degeneration.
✕Less likely to help
Patients with advanced wet age-related macular degeneration who are already receiving standard anti-VEGF treatments may not benefit from this research.
What this research studies
This research focuses on developing a new injectable treatment for age-related macular degeneration (AMD), a leading cause of blindness. The approach involves creating biodegradable nanoparticles that can release a therapeutic agent in response to inflammation caused by reactive oxygen species. By targeting the underlying inflammation and reducing the need for frequent injections, this study aims to improve patient outcomes and reduce treatment burden. The research will involve synthesizing and testing these nanoparticles to ensure they effectively deliver the therapeutic agent over an extended period.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less burdensome treatments for patients with age-related macular degeneration.
How similar studies have gone: Other research has shown promise in using nanoparticle delivery systems for therapeutics, suggesting potential success for this novel approach.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Swindle-Reilly, Katelyn E — Ohio State University
- Study coordinator: Swindle-Reilly, Katelyn E
Related research
Other NIH-funded projects on the same topics.
-
AI-powered tool to predict 2-year risk of late AMD
A new AI software helps people at risk of age-related macular degeneration understand their 2-year risk and what steps could protect their vision.
-
Active cycling program to support vision and daily living in Veterans with AMD
A 6-month online group spin cycling program is tested to help Veterans with age-related macular degeneration maintain vision and improve daily functioning.
-
Transplanting stem-cell–derived retinal cells to treat dry AMD
A medical team is testing a stem cell therapy to replace damaged retinal cells in adults with dry age-related macular degeneration.
-
RPESC-derived RPE Transplant for Dry AMD in adults
A new cell-based therapy derived from RPESCs is being tested to help adults with dry age-related macular degeneration regain vision.
-
New high-resolution OCT biomarkers to map early AMD changes
A new imaging approach using advanced OCT methods will help doctors see early changes in age-related macular degeneration to guide treatment and improve quality of life for older adults.
-
Targeting inflammation in age-related macular degeneration
Aims to understand how inflammation drives age-related macular degeneration in people and explore new targets to slow or stop vision loss.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.